CJC-1295 without DAC + Ipamorelin
Peptide Stack · Combination ConceptDual-pathway growth-hormone-release research
What Is This Combination?
ERP catalog context: CJC-1295 without DAC 5 mg + Ipamorelin 5 mg -- total 10 mg
A pairing of a GHRH-receptor-type signal with a ghrelin/GHS-receptor secretagogue signal, grounded in general dual-pathway GH-release physiology -- not a clinical trial of this exact commercial formulation.
The Concept
A GHRH-receptor agonist-type signal is paired with a ghrelin/GHS-receptor secretagogue signal. Older GHRH-plus-GHRP/GHS physiology research supports the existence of two distinct upstream pathways converging on growth-hormone release. That general physiology does not prove this exact commercial combination is safe, effective, or superior to either component alone.
Meet the Components
CJC-1295 without DAC
5 mgGHRH-receptor-type signaling arm
"CJC-1295 without DAC" is a marketplace label commonly equated with Modified GRF(1-29), though the naming is not consistently used across scientific and commercial sources. FDA's 2024 review distinguished CJC-1295 free base/acetate from DAC forms and found that most available clinical references concerned the DAC form specifically -- a separate evidence base for the non-DAC product as commonly sold has not been established.
Direct pharmacology, identity, characterization, efficacy, and safety data for the non-DAC form are limited, and duration/half-life findings from the DAC form do not transfer to this component. See the standalone Modified GRF(1-29) page for its full identity and evidence boundary.
Limited, identity-uncertain evidence
View CJC-1295 without DACresearch profile →Ipamorelin
5 mgghrelin/GHS-receptor secretagogue signaling arm
Ipamorelin is a selective ghrelin-receptor (GHS-R) agonist studied for stimulating growth-hormone release through a receptor pathway distinct from a GHRH-receptor agonist, providing the physiological basis for pairing it with a GHRH-type signal.
See the standalone Ipamorelin page for its full evidence summary.
Independent human secretagogue evidence
View Ipamorelinresearch profile →How the Roles Fit Together
What the Combination Is Intended to Address
Evidence-Supported Conceptual Domains
- GH pulse physiology
- GH/IGF-1 axis
- endocrine secretagogue research
- body-composition and recovery research
Community-Use Themes
The themes below are editorial summaries of commonly discussed community-use patterns. They are not controlled clinical evidence, systematically sourced community data, or established benefits.
- sleep and recovery discussions(editorial-summary)
- body composition discussions(editorial-summary)
- training recovery discussions(editorial-summary)
- "anti-aging" community framing(editorial-summary)
Concerns & Evidence Gaps
Safety Consideration
No strong exact-product clinical outcome evidence exists for this combination.Safety Consideration
Elevated GH/IGF-1 signaling may be undesirable in some contexts and has not been evaluated for this pairing specifically.Safety Consideration
Glucose-handling effects are a recognized concern with GH-axis stimulation generally.Safety Consideration
Fluid retention and edema are a recognized concern with GH-axis stimulation generally.Safety Consideration
Paresthesia and carpal-tunnel-type effects are recognized concerns with GH-axis stimulation generally.Safety Consideration
Long-term combination safety is unknown.Safety Consideration
DAC/no-DAC naming confusion in the marketplace means the non-DAC component's exact identity and evidence base cannot be assumed to match DAC-form CJC-1295 literature.
Why Separate Components May Sometimes Be Preferable
Presented as a scientific/practical tradeoff, not a recommendation.
Favoring Separate Administration
- Administering the GHRH-type and GHS-type signals independently allows each pathway's effects to be evaluated on its own.
- The non-DAC component's own identity and evidence uncertainty is easier to reason about when it is not combined with a second, differently-evidenced compound.
- No evidence-derived optimal ratio between the two components has been established.
- Independent administration allows either signaling arm to be held or stopped without affecting the other.
Favoring the Fixed-Ratio Blend
- A single combined vial is more convenient to source and administer than two separate components on two schedules.
Convenience is not evidence of biological superiority.
Evidence Boundary
The components of this combination have been investigated individually to varying degrees. Evidence for an individual component does not automatically establish the safety, efficacy, compatibility, or synergy of the exact combination. Where direct combination studies exist, MitoCore identifies that explicitly. Where they do not, the page describes the biological rationale for the combination rather than presenting the stack itself as a validated therapeutic intervention.
Exact-combination status: General GHRH-plus-GHS/GHRP dual-pathway physiology is described in the broader research literature, supporting the existence of two converging pathways to growth-hormone release. No clinical trial of this exact commercial formulation was located, and the non-DAC component's own identity and evidence base carry additional uncertainty.
Limitations: This 'limited' status refers to general dual-pathway growth-hormone-release physiology, not a clinical trial of this exact formulation. It does not establish safety, efficacy, an optimal ratio, or that combining the two produces a greater effect than either alone.
Component evidence: Evidence strength varies by component, and the non-DAC component in particular carries identity and evidence-base uncertainty distinct from the DAC form -- see each component's own standalone page.
Explore the Components
Each component's full evidence base lives on its own standalone research profile.
Modified GRF(1-29)
“CJC-1295 without DAC” is a marketplace label that is often equated with Modified GRF(1-29), but the naming is not consistently used in scientific and commercial sources. FDA’s 2024 review distinguished CJC-1295 free base or acetate from DAC forms and found that the available clinical references largely concerned CJC-1295 DAC. A separate evidence base for the non-DAC product as commonly sold was not established.
View research profile →Ipamorelin
Ipamorelin is a ghrelin-receptor agonist and growth-hormone secretagogue. Human research confirms that it can trigger an acute GH pulse, but the principal phase 2 clinical trial for postoperative ileus did not meet its primary efficacy endpoint. Evidence does not establish common claims involving sleep, recovery, body composition, or anti-aging, and FDA has highlighted serious safety and product-characterization concerns for compounded injectable use.
View research profile →Disclaimer
See the anecdotal notice above for community-discussion context.
This page does not establish combination efficacy, safety, or compatibility beyond what is explicitly cited above. Always review each component's own standalone research profile for its full evidence base.